Scott Olson/Getty Images
- Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported.
- Roivant made $5 billion from the sale, after having only spent $15 million on development.
- Pfizer originally passed it over to Roivant for free last December.
Roche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported.